NCI Study: More Than 2 Million U.S. Women Could Benefit from Tamoxifen
Magazine article; FDA Consumer, Vol. 37, May-June 2003
Subjects:
...approved as a chemoprevention drug for breast cancer by the FDA in 1998, after the NCI released the results of the Breast Cancer Prevention Trial (BCPT), a six-year study of the drug. In BCPT, tamoxifen was found to reduce the incidence of breast cancer...